Ophthalmology Glaucoma

Slides:

Advertisements

Similar presentations

Anupama Kotha 1, Simar J. Singh 1, William B. Trattler 1,2, Carlos Buznego 1,2 The authors have no financial interest in the subject matter of this poster.

Advertisements

Anterior Chamber Depth, Iridocorneal Angle Width, and Intraocular Pressure Changes After Phacoemulsification: Narrow vs Open Iridocorneal Angles Huang.

Phacoemulsification with Goniosynechialysis in the Management of Refractory Acute Angle-closure Glaucoma Ghasem Fakhraie*, MD, Mahmoud Jabbarvand, MD,

Neeti Parikh, MD Fuxiang Zhang, MD Department of Ophthalmology Henry Ford Hospital A Comparison Of Patient Satisfaction With Modified Monovision Versus.

Purpose: Introduction:  At initial evaluation: For post-op day # 0 patients: Pre-op VA was 20/50.6 (0.395 ± 0.198); Post-op VA was 20/102.0 (0.196 ± 0.162);

>>0 >>1 >> 2 >> 3 >> 4 >> FULL PANRETINAL PHOTOCOAGULATION IMPROVES THE OUTCOME OF TRABECULECTOMY IN NEOVASCULAR GLAUCOMA Saleh alobeidan MD Essam osman.

Glaucoma and Penetrating Keratoplasty : Incidence, Risk Factors, and Outcomes Sonika Gupta Consultant Ophthalmology Max Eye Care New Delhi, India Author.

Combined cataract surgery and endoscopic cyclophotocoagulation in patients with glaucoma without prior incisional glaucoma surgery Matthew P. Traynor,

PHACO-TRAB VERSUS PHACO ONLY IN EYES WITH ADVANCED OR END-STAGE GLAUCOMA WITH CONTROLLED INTRAOCULAR PRESSURE AND VISUALLY SIGNIFICANT CATARACT Liaska.

Glaucoma Care Project Team Members: Geoffrey T. Emerick, M.D. Erin Herlihy, B.S. Marilyn Hauser, M.B.A. Dianna Greening, R.N. Walter M. Jay, M.D Opportunity.

4/3/2016 U F G Universidade Federal de Goiás C B C O Centro Brasileiro de Cirurgia de Olhos A Prospective, Comparative Study Between Endoscopic Cyclophotocoagulation.

Mr. A. Waldock MD BMed Sci (Hons) BM BS FRCOphth Consultant Ophthalmic Surgeon Ophthalmology Training Programme Director, East of England Deanery.

iStent with phacoemulsification, n=50

Iwona Helemejko, MD 1; D. Robert Iskander, PhD2

Pseudoexfoliation syndrom and cataract: results and complication frequency in immature and mature cataract surgery Marijana Bilen Babić Department of.

IMPACT OF CATARACT SURGERY UPON INTRAOCULAR PRESURE CONTROL IN GLAUCOMA PATIENTS Crenguta Feraru, Anca Pantalon “Gr.T. Popa” University of Medicine and.

Copyright © 2011 American Medical Association. All rights reserved.

Volume 121, Issue 12, Pages (December 2014)

Analysis of Macular Edema after Cataract Surgery in Patients with Diabetes Using Optical Coherence Tomography Stephen J. Kim, MD, Robert Equi, MD, Neil.

IOP control and corneal endothelial cell density changes

LONG-TERM RESULTS OF DEEP SCLERECTOMY IN NORMAL-TENSION GLAUCOMA

A one-year audit of topics and domains in the Journal of the American Medical Association and the New England Journal of Medicine1 Steven H Woolf, MD,

Volume 121, Issue 12, Pages (December 2014)

American Journal of Ophthalmology

V. Kumar,1,2 M. Frolov,1 E. Bozhok,2 G. Dushina1

Early Intraocular Pressure Rise After Phacoemulsification In Non-Glaucomatous And Eyes With Primary Open-Angle Glaucoma Milos Todorovic 1, Suncica Sreckovic.

Hayashi Eye Hospital, Fukuoka, Japan

Volume 123, Issue 6, Pages (June 2016)

Trauma z Surgical treatment of extremely complicated forms of glaucoma

Randal Pham, Burton Worrell, Phuc Nguyen, Keshav Narain

Andrew A. Moshfeghi, MD, MBA, Howard Shapiro, PhD, Linda A

B. Kozomara, E. Potkonjak, R. Lazic, N. Gabric

A presentation to: Meeting name Date

From: Prostaglandin Analogues and Mouse Intraocular Pressure: Effects of Tafluprost, Latanoprost, Travoprost, and Unoprostone, Considering 24-Hour Variation.

Volume 1, Issue 4, Pages (July 2017)

Conjunctival Goblet Cell Density Following Cataract Surgery With Diclofenac Versus Diclofenac and Rebamipide: A Randomized Trial Kumiko Kato, Kensaku.

A presentation to: Meeting name Date

A presentation to: Meeting name Date

Successful cataract surgery in a patient with refractory Wegener’s granulomatosis effectively treated with rituximab: A case report Abdullah M. Alfawaz

Preoperative Characteristics

Volume 121, Issue 4, Pages (April 2014)

Transscleral Diode Laser Cyclophotocoagulation

Prospective Randomized Trial Comparing Mitomycin C Combined with Ologen Implant versus Mitomycin C Alone as Adjuvants in Trabeculectomy Mrittika Sen,

Association between Rates of Retinal Nerve Fiber Layer Thinning and Previous Disc Hemorrhage in Glaucoma Tadamichi Akagi, MD, Luke J. Saunders, PhD,

DW.Lee, NC Cho, MJ Kim, EY Kwen

Distribution and Rates of Visual Field Loss across Different Disease Stages in Primary Open-Angle Glaucoma Siamak Yousefi, PhD, Golnoush Sadat Mahmoudi.

Robert J Cerfolio, MD, Cyndi Bass, MSN, Charles R Katholi, PhD

J. Alexander Torres, BS, Nathan A. Fischer, BS, Leonard K

Treatment Outcomes of Mitomycin C-Augmented Trabeculectomy, Sub-Tenon Injection versus Soaked Sponges, after 3 Years of Follow-up Hamed Esfandiari, MD,

A presentation to: Meeting name Date

Aaron Z. Priluck, BSE, Jamie Dietze, BS Ophthalmology Glaucoma

Amedeo Anselmi, MD, Gianfederico Possati, MD, Mario Gaudino, MD

Alex S. Huang, MD, PhD, Rafaella C

Erin G. Sieck, MD, Rebecca S. Epstein, MD, Jeffrey B

Improving the Feasibility of Glaucoma Clinical Trials Using Trend-Based Visual Field Progression End Points Zhichao Wu, BAppSc(Optom), PhD, David P.

Detecting Glaucoma Progression Using Guided Progression Analysis with OCT and Visual Field Assessment in Eyes Classified by International Classification.

Correlation between Intraocular Pressure and Angle Configuration Measured by OCT Benjamin Y. Xu, MD, PhD, Bruce Burkemper, PhD, Juan Pablo Lewinger, PhD,

A presentation to: Meeting name Date

Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: A meta-analysis of randomized trials Roberta J. Navickis, PhD, Gary R. Haynes,

Standalone Ab Interno Gelatin Stent versus Trabeculectomy

Development of a Novel Corneal Concavity Shape Parameter and Its Association with Glaucomatous Visual Field Progression Shuichiro Aoki, MD, Hiroshi Murata,

Micropulse Transscleral Cyclophotocoagulation

Ophthalmology Glaucoma

Ophthalmology Glaucoma

Acute Stress Increases Intraocular Pressure in Nonhuman Primates

Safety and Efficacy of Mapracorat Ophthalmic Suspension in the Treatment of Inflammation Following Cataract Surgery: Adaptive Design Study Timothy L.

Ophthalmology Glaucoma

Yinin Hu, MD, Timothy L. McMurry, PhD, Kristen M. Wells, PhD, James M

Yue Shi, MD, PhD, Xin Yang, MD, PhD, Kenneth M

Stephen G Slade, MD The Laser Center of Houston Houston, Texas

Presentation transcript:

Ophthalmology Glaucoma Five-Year, Prospective, Randomized, Multi-Surgeon Trial of Two Trabecular Bypass Stents versus Prostaglandin for Newly Diagnosed Open-Angle Glaucoma Robert D. Fechtner, MD, Lilit Voskanyan, MD, PhD, Steven D. Vold, MD, Manfred Tetz, MD, Gerd Auffarth, MD, Imran Masood, FRCOphth, Leon Au, FRCOphth, Albert S. Khouri, MD, Iqbal Ike K. Ahmed, MD, Hady Saheb, MD Ophthalmology Glaucoma DOI: 10.1016/j.ogla.2019.03.004 Copyright © 2019 American Academy of Ophthalmology Terms and Conditions

Figure 1 Mean intraocular pressure (IOP) through 5 years postoperatively, regardless of add-on medication. IOP excludes data from eyes after cataract surgery. Add-on medication = any medication in stent group or a second medication in travoprost group; M = month; n = number of eyes; SCR = screening. Ophthalmology Glaucoma DOI: (10.1016/j.ogla.2019.03.004) Copyright © 2019 American Academy of Ophthalmology Terms and Conditions

Figure 2 Time to starting add-on medication. Excludes data from eyes after cataract surgery. Add-on medication = any medication in stent group or a second medication in travoprost group. IOP = intraocular pressure; SCR = screening. Ophthalmology Glaucoma DOI: (10.1016/j.ogla.2019.03.004) Copyright © 2019 American Academy of Ophthalmology Terms and Conditions

Figure 3 Mean intraocular pressure (IOP) through 5 years postoperative for eyes without add-on medication. IOP excludes data from eyes after cataract surgery. Add-on medication = any medication in stent group or a second medication in travoprost group; M = month; n = number of eyes. Ophthalmology Glaucoma DOI: (10.1016/j.ogla.2019.03.004) Copyright © 2019 American Academy of Ophthalmology Terms and Conditions

Figure 4 Eyes achieving treatment success through 5 years (intraocular pressure [IOP] 6–18 mmHg inclusive without add-on medication or secondary glaucoma surgery). Excludes data from eyes after cataract surgery. Excludes all eyes with medication added, even if IOP was in success range of 6–18 at the time it was added. Add-on medication = any medication in stent group or a second medication in travoprost group; M = month; n = number of eyes. Ophthalmology Glaucoma DOI: (10.1016/j.ogla.2019.03.004) Copyright © 2019 American Academy of Ophthalmology Terms and Conditions

Figure 5 Eyes achieving 5-year unmedicated intraocular pressure (IOP) of 6–18 mmHg without secondary glaucoma surgery, including eyes with medication added for non-IOP reasons. Excludes data from eyes after cataract surgery. Includes data from eyes with medication added because of optic nerve findings, despite IOP within target of 6 to 18 mmHg. This includes 2 stent eyes (IOP 16 and 18, respectively) and 3 travatan eyes (IOP 18). M = month; n = number of eyes; Preop = preoperatively. Ophthalmology Glaucoma DOI: (10.1016/j.ogla.2019.03.004) Copyright © 2019 American Academy of Ophthalmology Terms and Conditions

Figure 6 Proportional analysis of best-corrected visual acuity (BCVA) through 5 years postoperative. Preop = preoperative. Ophthalmology Glaucoma DOI: (10.1016/j.ogla.2019.03.004) Copyright © 2019 American Academy of Ophthalmology Terms and Conditions